Quantcast

Latest Novartis Pharmaceuticals Corporation Stories

2014-10-21 08:28:24

Through music and resources Our Voice in Song(TM) inspires people living with relapsing MS to become more active managers of their disease EAST HANOVER, N.J., Oct. 21, 2014 /PRNewswire/ -- Today Novartis Pharmaceuticals Corporation launched a new multifaceted multiple sclerosis (MS) awareness campaign aimed to motivate people with relapsing MS to take charge of their disease. The campaign, Our Voice in Song(TM), features inspirational advocate and music artist David Osmond, who...

2014-10-20 16:27:09

- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015 EAST HANOVER, N.J., Oct. 20, 2014 /PRNewswire/ -- Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) today voted 7 to 0 to support the approval of AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, for the treatment...

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST HANOVER, N.J., Oct. 15, 2014 /PRNewswire/ -- Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients...

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-23 23:06:16

Best of the Best in Healthcare Marketing Honored at Gala Event NEW YORK, NY (PRWEB) September 23, 2014 PM360, a leading health-marketing industry trade magazine, recognized the best innovators in the pharmaceutical industry with their annual Trailblazer Awards on Thursday, September 18, 2014. The honors, bestowed at a gala banquet at Gotham Hall in New York City, are given to outstanding companies, marketers and brand managers representing top talent and brands. “This industry...

2014-08-30 08:20:58

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug. 30, 2014 /PRNewswire/ -- Today at the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever...

2014-08-11 00:20:49

-- LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF EAST HANOVER, N.J., Aug. 11, 2014 /PRNewswire/ -- New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress, the European Society of Cardiology (ESC) Congress 2014, on Sunday...

2014-07-09 16:28:56

- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints[1] EAST HANOVER, N.J., July 9, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published the results from two pivotal Phase III studies evaluating the interleukin-17A (IL-17A) inhibitor secukinumab (AIN457). Secukinumab met all primary and key secondary...

2014-07-07 12:29:12

- Designation supports the advancement of CTL019 to help address the unmet need of patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) EAST HANOVER, N.J., July 7, 2014 /PRNewswire/ -- Novartis announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related